Cystic Fibrosis
Rationale 1,6
NHS England Specialist Commissioning: Prescribing to remain with specialist centre April 2014
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Treatment of the following infections in adults: Complicated intra-abdominal infection; hospital-acquired pneumonia, including ventilator-associated pneumonia; complicated urinary tract infection, including pyelonephritis. Also treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
Rationale 1
*Hospital Use Only*
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Primaxin
Aerobic and anaerobic gram-positive and gram-negative infections; surgical prophylaxis; hospital-acquired septicaemia
Rationale: 1,2
NICE NG14 Melanoma: assessment and management
Advice for healthcare professionals:
* A clinically significant interaction between carbapenems and valproic acid/sodium valproate results in reduced valproate plasma concentrations with potential for inadequate seizure control
* Given the large magnitude and rapid time course of this interaction, monitoring of sodium valproate levels or making dose adjustments are unlikely to manage this interaction
* Concomitant use of carbapenems in patients taking valproic acid/sodium valproate is not recommended, and prescribers should consider alternative antibacterial therapy
MHRA Drug Safety Update Volume 3 Issue 10 May 2010
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections
Aerobic and anaerobic gram-positive and gram-negative infections
Rationale 1
Advice for healthcare professionals:
* A clinically significant interaction between carbapenems and valproic acid/sodium valproate results in reduced valproate plasma concentrations with potential for inadequate seizure control
* Given the large magnitude and rapid time course of this interaction, monitoring of sodium valproate levels or making dose adjustments are unlikely to manage this interaction
* Concomitant use of carbapenems in patients taking valproic acid/sodium valproate is not recommended, and prescribers should consider alternative antibacterial therapy
MHRA Drug Safety Update Volume 3 Issue 10 May 2010
Please refer to the NICE Summary of antimicrobial prescribing guidance - managing common infections. See link in section 5 Infections